Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Table 5

Presence of refractive errors of the ROP patients treated with ranibizumab or bevacizumab at the corrected age of 3 years.

	Ranibizumab ()	Bevacizumab ()
High myopia (≤−5 D)	0 (0%)	6 (16.7%)	0.03
Myopia (high + low) (≤−1 D)	4 (15.4%)	7 (19.4%)	0.75
High hyperopia (>+4 D)	0 (0%)	1 (2.8%)	1.00
Hyperopia (high + low) (>+1 D)	2 (7.7%)	12 (33.3%)	0.03
Presence of ametropia (>+1 D or <−1 D)	6 (23.1%)	19 (52.8%)	0.03

Fisher’s exact test.